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Leucine-rich glioma-inactivated protein
1 antibody encephalitis
A case report
ABSTRACT
Objective: To describe a case of leucine-rich glioma-inactivated protein 1 (LGI1) antibody–associated
encephalitis.
Methods: The clinical and ancillary data and brain MRIs were gathered retrospectively by chart
review. Relevant literature on similar cases was also reviewed.
Results: The diagnosis of LGI1 antibody–associated autoimmune encephalitis was based on the
typical clinical presentation of seizures, psychiatric symptoms, and memory loss as well as neg-
ative diagnostic testing for cancer; the diagnosis was confirmed by positive LGI1 antibody. The
patient responded favorably to treatment with IV immunoglobulin and continues to do well.
Conclusion: LGI1 antibody–associated encephalitis has increasingly been recognized as a pri-
mary autoimmune disorder with good prognosis and response to treatment. Neurol Neuroimmunol
Neuroinflamm 2014;1:e51; doi: 10.1212/NXI.0000000000000051
GLOSSARY
AMPA 5 a-amino-3-hydroxy-5-methyl-isoxazoleproionic acid; Caspr2 5 contactin-associated protein-like 2; GABAB 5
g-aminobutyric acid B; HSV5 herpes simplex virus; Ig5 immunoglobulin; IVIg5 IV immunoglobulin; LE5 limbic encephalitis;
LGI15 leucine-rich glioma-inactivated protein 1;NMDA5N-methyl-d-aspartate;VGKC5 voltage-gated potassium channel.
Limbic encephalitis (LE) has traditionally been described as a paraneoplastic syndrome associated
with onconeural antibodies induced by the neoplasm and directed against intracellular antigens,
with the usual clinical presentation of subacute dementia, seizures, and psychiatric disturban-
ces.1-3 A distinct group of autoimmune encephalitis not associated with malignancy and with
antibodies targeting extracellular antigens has recently been recognized and termed neuronal
surface antibody syndrome or autoimmune synaptic encephalitis.3-6 These neuronal surface
antibodies target the neuronal cell surface or synaptic proteins, including NMDA, a-amino-
3-hydroxy-5-methyl-isoxazoleproionic acid (AMPA), and g-aminobutyric acid B (GABAB)
receptors.7,8 Leucine-rich glioma-inactivated protein 1 (LGI1) and contactin-associated
protein-like 2 (Caspr2) have recently been identified as specific target proteins in most cases
of autoimmune encephalitis previously believed to be associated with antibodies against voltage-
gated potassium channel (VGKC) complex.9,10 We describe a case of LGI1 antibody–associated
encephalitis with excellent response to immunotherapy.
CASE REPORT A 62-year-old Caucasian man who was diagnosed with REM sleep behavior disorder 6
months prior to presentation presented with new-onset complex partial with secondary generalized seizures
without any associated systemic or other neurologic symptoms. This was followed by progressive cognitive
decline and psychiatric symptoms including depression, anxiety, and paranoia within 2 months. The
neurologic examination was consistent with dementia without any focal motor or sensory deficits. He
underwent extensive diagnostic workup, which was unrevealing for any apparent etiology. The routine
laboratory studies were normal except for persistent hyponatremia. The serologic tests for systemic
infection, including peripheral CD4 count, serum HIV 1 and 2 and human T lymphotropic virus 1 and 2
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antibodies, hepatitis panel, syphilis immunoglobulin
(Ig) G antibody, Mycobacterium tuberculosis antigen
lymphocyte stimulation assay, Aspergillus antigen and
antibody, and urine Legionella antigen screen, were all
negative. A serum autoantibody panel showed only
mild elevation of anti-RNP antibody at 2.3 units
antibody index (normal ,1 antibody index).
CSF analysis revealed slightly elevated protein
level of 50 mg/dL (normal range 15-45 mg/dL), nor-
mal cell count and glucose level, and sterile bacterial
and fungal cultures. Screening for herpes simplex
virus (HSV) 1 and 2; enterovirus, varicella-zoster
virus, and John Cunningham virus by PCR; Borrelia
burgdorferi antibody; and Venereal Disease Research
Laboratory was negative. Oligoclonal bands in CSF
were not detected. The IgG index was elevated at
0.74 (normal range 0.28-0.66). HSV 2 IgG antibody
level was elevated at 1.52 index value (normal range
,0.89 index value). HSV 1 and 2 IgM antibodies
were negative.
Brain MRI showed minimally increased signal in
the cortices of the medial temporal lobes (figure, A)
beside nonspecific white matter T2 hyperintensities
on the fluid-attenuated inversion recovery sequence
(figure, B). EEG showed diffuse slowing of back-
ground rhythm. A 4-vessel cerebral angiogram
showed normal intracranial and extracranial vascula-
ture. Leptomeningeal and cortical (right frontal)
biopsy was also obtained; the histology showed no
evidence of vasculitis, inflammation, infection, neo-
plasm, or any other pathologic process within the
dura, arachnoid, or cortex.
The patient’s clinical condition continued to
decline, with worsening cognitive function and psy-
chiatric symptoms including confusion, agitation,
paranoid behavior, and aggression. He continued to
have recurrent generalized seizures despite being on
optimal dosage of multiple antiepileptic medications.
He was empirically treated with high-dose IV gluco-
corticoids with no significant clinical improvement.
Given the clinical presentation of progressive
encephalopathy syndrome with worsening neuropsy-
chiatric symptoms and refractory seizures, the diagno-
sis of LE was considered and further diagnostic testing
was undertaken in search of occult systemic malig-
nancy. CT scan of chest, abdomen, and pelvis did
not reveal any evidence of cancer. Scrotal Doppler
ultrasound showed a right testicular mass lesion sus-
pected to be neoplasm, which on biopsy was found
to be a focal parenchymal infarction. At this point,
the diagnosis of nonparaneoplastic LE was suspected
and the screening test for VGKC-complex antibody
using radioimmunoassay showed an elevated level of
688 pmol/L (normal range ,450 pmol/L). Addi-
tional testing for LGI1 and Caspr2 antibody by indi-
rect immunofluorescence staining (cell-based assay)
showed positive LGI1 antibody and negative Caspr2
antibody.
The patient was subsequently treated with a 5-day
(400 mg/kg/day) course of IV immunoglobulin
(IVIg). He had excellent clinical response to IVIg
treatment, with resolution of seizures and psychiatric
symptoms. His mental status and cognitive function
improved to his premorbid baseline within a few
weeks. Currently, the patient is receiving mainte-
nance IVIg treatment (200 mg/kg) every 3 months.
He continues to do well clinically, independently
performing his activities of daily living.
DISCUSSION Our case demonstrates the impor-
tance of high suspicion for LGI1 antibody–induced
LE in a patient with seizures and rapidly progressive
dementia because these patients respond remarkably
well to IVIg. Our patient underwent extensive inves-
tigation including brain biopsy that would have been
avoided with an early diagnosis of autoimmune LE.
LE is a group of immune-mediated disorders that
encompasses the classic paraneoplastic encephalitis
syndromes that are associated with onconeural
antibodies directed against intracellular (nuclear
or cytoplasmic) antigens and the more recently
described nonparaneoplastic autoimmune enceph-
alitides that are mostly associated with antibodies
against extracellular (neuronal cell surface or syn-
aptic) antigens.3,5-7 The antigens in cases of non-
paraneoplastic autoimmune LE include VGKC
complex, NMDA, AMPA, glycine, or GABAB
receptor.2,7,10-12 The initial reports suggested that
the antibodies against VGKC complex bind Kv1.1
and Kv1.2; however, the recent studies have shown
LGI1 and Caspr2 to be the specific targets.9,10,13,14
Typical clinical presentation of LE associated with
LGI1 antibody includes cognitive decline, behav-
ioral disturbance, and seizures.9,10 The clinical
Figure Brain MRI
Brain MRI axial fluid-attenuated inversion recovery (FLAIR) image shows ill-defined
increased signal in the medial temporal lobes bilaterally (A). Axial FLAIR slice through the
basal ganglia demonstrates multiple other nonspecific white matter T2 hyperintensities (B).
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presentation in our case was fairly typical, with
dementia, psychiatric symptoms, and seizures.
The other specific clinical features seen in patients
with LGI1 encephalitis include faciobrachial dys-
tonic seizures, which can precede the other classic
symptoms of LE,14,15 and hyponatremia.10,14 Our
patient did not have the typical faciobrachial dys-
tonic seizures, but he did present with the charac-
teristic hyponatremia. The brain MRI in LGI1
antibody encephalitis cases may be normal or show
increased T2 signal in bilateral temporal lobes, as
was seen in our patient.14,15 Most cases of LGI1
encephalitis are nonparaneoplastic; the diagnosis
of LGI1 encephalitis in our case was established
by positive LGI1 antibody in the absence of sys-
temic malignancy.
Patients with encephalitis associated with antibod-
ies to cell surface and synaptic antigens, such as LGI1
encephalitis, respond better to immune-based thera-
pies due to the direct pathogenic role of these autoan-
tibodies, in contrast to the cases with antibodies
directed against intracellular antigens such as Hu pro-
teins or Ma 2, which are believed to cause T-cell–
mediated neuronal degeneration that responds poorly
to immune-based therapies.3,5,7,14 LGI1 is a glycopro-
tein secreted from presynaptic terminals that binds
to presynaptic disintegrin and metalloproteinase
domain-containing protein 23 (ADAM23) and post-
synaptic ADAM22 and plays an important role in
synaptic transmission by regulating the presynaptic
Kv1.1 and Kv1.2 subunits and AMPA receptors.5,10
LGI1 antibodies may prevent binding of LGI1 to the
receptors it regulates, disrupt currents mediated by
Kv1.1 and Kv1.2, and impair AMPA receptor func-
tion.5 The pathogenic role of LGI1 antibodies is sup-
ported by observed clinical improvement with
immunotherapy in most of these cases.8,14,15 Combi-
nation immunotherapy with steroids and IVIg may
be superior to monotherapy with either agent alone
with less relapse risk, although these observations are
based on experience in small case series.14 The clinical
improvement following IVIg treatment in our patient
supports the notion of the pathogenic role of LGI1
antibodies.
We present a case that highlights the importance
of early screening for LE in a patient presenting with
relatively rapidly progressive cognitive decline and
seizures with no clear etiology. As an increasing num-
ber of autoimmune nonparaneoplastic LE cases are
being recognized, it is important to screen patients
with suspected LE for the presence of neuronal
surface antibodies, including LGI1 antibodies, in
addition to conducting a search for systemic malig-
nancy. Early diagnosis and treatment with immuno-
therapy such as IVIg can lead to rapid resolution of
clinical symptoms in these patients.
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